Status:

COMPLETED

The Effect of Remote Ischemic Preconditioning in Living Donor Hepatectomy

Lead Sponsor:

Asan Medical Center

Conditions:

Tissue Donors

Liver Transplantation

Eligibility:

All Genders

18-60 years

Phase:

NA

Brief Summary

Liver transplantation is the gold standard treatment for patients with end-stage liver disease. Despite its outstanding success, liver transplantation still entails certain complications including isc...

Detailed Description

Liver transplantation(LT) is the gold standard treatment for patients with end-stage liver disease. In light of advancements in surgical techniques, immunosuppressive agents, and perioperative critica...

Eligibility Criteria

Inclusion

  • Donors who plan to have living right hepatectomy for liver transplantation.
  • age : between 18 to 60 years.

Exclusion

  • donors who plan to donate left lobe
  • donors who plan to have laparoscopic right hepatectomy
  • donors who cannot proceed remote ischemic preconditioning

Key Trial Info

Start Date :

August 22 2016

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 30 2017

Estimated Enrollment :

160 Patients enrolled

Trial Details

Trial ID

NCT03386435

Start Date

August 22 2016

End Date

October 30 2017

Last Update

August 19 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Asan medical center

Seoul, Songpa-gu, South Korea, 05505

The Effect of Remote Ischemic Preconditioning in Living Donor Hepatectomy | DecenTrialz